Neurocrine CMO vests 3,914 shares, some withheld

Neurocrine Biosciences’ chief medical officer received vested stock from PRSUs, with a portion withheld to cover taxes and no market sale of shares.

Rhea-AI Filing Summary

NEUROCRINE BIOSCIENCES INC (NBIX) reported that Chief Medical Officer Sanjay Chandru Keswani had performance restricted stock units vest upon achievement of a certified performance metric on September 11, 2026, resulting in an acquisition of 3,914 shares of common stock. On the same date, 2,112 shares were withheld by the company at $156.22 per share to satisfy tax withholding requirements on the vesting; the company states that no shares were sold in the market.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Keswani Sanjay Chandru

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	3,914	$0.00	$0.00
Tax Withholding	Common Stock F2	2,112	$156.22	$330K

Holdings After Transaction: Common Stock — 3,281 shares (Direct)

Footnotes (2)

1. F1. The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.
2. F2. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

Key Figures

Shares acquired from PRSU vesting: 3,914 shares Shares withheld for taxes: 2,112 shares Tax withholding price per share: $156.22 per share

3 metrics

Shares acquired from PRSU vesting 3,914 shares Common stock acquired on September 11, 2026 upon certification of a performance metric

Shares withheld for taxes 2,112 shares Withheld by Neurocrine Biosciences on September 11, 2026 to satisfy tax withholding

Tax withholding price per share $156.22 per share Applied to 2,112 shares of common stock withheld for tax obligations

Key Terms

performance restricted stock units (PRSUs), tax withholding requirements, Chief Medical Officer

3 terms

performance restricted stock units (PRSUs) financial

"The Reporting Person was previously granted performance restricted stock units (PRSUs)"

tax withholding requirements financial

"Shares withheld by Neurocrine Biosciences, Inc. to satisfy tax withholding requirements"

Chief Medical Officer other

"Keswani Sanjay Chandru, Chief Medical Officer"

A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did NBIX’s Chief Medical Officer report on September 11, 2026?

On September 11, 2026, NBIX’s Chief Medical Officer Sanjay Chandru Keswani reported vesting of performance restricted stock units for 3,914 common shares, and the withholding of 2,112 shares to cover tax obligations related to that vesting.

Were any Neurocrine Biosciences (NBIX) shares sold in the open market in this Form 4?

No. The filing states that no shares were sold. Instead, 2,112 shares of NBIX common stock were withheld by Neurocrine Biosciences to satisfy tax withholding requirements upon vesting of performance restricted stock units.

How many NBIX shares did the CMO acquire from PRSU vesting in this Form 4?

Chief Medical Officer Sanjay Chandru Keswani acquired 3,914 shares of NBIX common stock upon vesting of previously granted performance restricted stock units, following certification of achievement of a specified performance metric on September 11, 2026.

What was the tax withholding price per share for the NBIX shares withheld?

The company withheld 2,112 shares of NBIX common stock to meet tax withholding requirements at a price of $156.22 per share, as reported in the Form 4 for September 11, 2026.

What triggered the vesting of PRSUs reported for NBIX’s Chief Medical Officer?

The vesting was triggered when Neurocrine Biosciences certified achievement of one of the performance metrics attached to previously granted performance restricted stock units on September 11, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/15/2026 - 05:06 PM Accepted by SEC EDGAR 09/15/2026 - 05:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keswani Sanjay Chandru

(Last) (First) (Middle)

6027 EDGEWOOD BEND CT.

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
NEUROCRINE BIOSCIENCES INC [ NBIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/11/2026		A(1)		3,914	A	$0	5,393	D
Common Stock	09/11/2026		F(2)		2,112	D	$156.22	3,281	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person was previously granted performance restricted stock units (PRSUs) that vest upon the achievement of certain performance metrics, the achievement of one of which was certified on September 11, 2026.

2. Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of PRSUs. No shares were sold.

Remarks:

	/s/ Darin Lippoldt, Attorney-in-Fact	09/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)